FORMULATION AND CHARACTERIZATION OF PAPAIN LOADED SOLID LIPID NANOPARTICLES AGAINST HUMAN COLORECTAL ADENOCARCINOMA CELL LINE
DOI:
https://doi.org/10.22159/ajpcr.2018.v11i10.27258Keywords:
Papain, Solid lipid nanoparticles, Cytotoxic potential, Proteolytic enzyme, In vitro drug releaseAbstract
Objective: Colorectal cancer is one of the most commonly diagnosed cancer and also most common gastrointestinal malignancy with high prevalence rate in the younger population. Usually, cancer cells are surrounded by a fibrin coat which is resistant to fibrinolytic degradation. This fibrin coat is act as self-protective against natural killing mechanism. The main objective was to prepare papain-loaded solid lipid nanoparticles (P-SLN) by melt dispersion-ultrasonication method and investigated the cytotoxic efficacy against colorectal adenocarcinoma (human colorectal adenocarcinoma [HCT 15]) cells.
Methods: Optimized polymer ratio was characterized by differential scanning calorimetry, Fourier-transform infrared, X-ray diffraction, scanning electron microscopy, entrapment efficiency, particle size and zeta potential analysis, in vitro drug release, and in vitro cytotoxicity studies on HCT-15 colorectal adenocarcinoma cells.
Results: The results showed that the particle size, morphological character and zeta potential value of optimized batch P-SLN were 265 nm, spherical and −26.5 Mv, respectively. The in vitro drug profile of P-SLN exhibited that it produced sustain drug release, and the cell viability of HCT-15 against P-SLN shown better efficacy than pure papain enzyme.
Conclusion: P-SLNs were successfully prepared and investigated the in vitro drug release and in vitro cell viability against HCT-15 cell line.
Downloads
References
Cisterna BA, Kamaly N, Choi WI, Tavakkoli A, Farokhzad OC, Vilos C, et al. Targeted nanoparticles for colorectal cancer. Nanomedicine (Lond) 2016;11:2443-56.
Goldberg RM, Rothenberg ML, Van Cutsem E, Benson AB 3rd, Blanke CD, Diasio RB, et al. The continuum of care: A paradigm for the management of metastatic colorectal cancer. Oncologist 2007;12:38 50.
Fornarini G, Guglielmi A, Sobrero A. The handling of metastatic colorectal cancer. Ann Oncol 2005;16 Supplement 2:141-3.
Dallas NA, Xia L, Fan F, Gray MJ, Gaur P, van Buren G 2nd, et al. Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Res 2009;69:1951-7.
Lipinski B. Iron-induced parafibrin formation in tumors fosters immune evasion. Oncoimmunology 2014;3:e28539.
Keith IB, Barry BD, Nicholas G, Aristo V. The Immune system in cancer. Integrative Cancer Ther 2002;1:294-316.
Vicente LC, Aires-Barros R, Empis JM. Stability and proteolytic activity of papain in reverse micellar and aqueous media: A kinetic and spectroscopic study. J Chem Technol Biotechnol 1994;60:291-7.
Mukherjee S, Ray S, Thakur RS. Solid lipid nanoparticles: A modern formulation approach in drug delivery system. Indian J Pharm Sci 2009;71:349-58.
Gamal AS. Ciprofloxacin controlled-solid lipid nanoparticles: Characterization, in vitro release, and antibacterial activity assessment. Biomed Res Int 2017;2120734:9.
Pooja D, Tunki L, Kulhari H, Reddy BB, Sistla R. Optimization of solid lipid nanoparticles prepared by a single emulsification-solvent evaporation method. Data Brief 2016;6:15-9.
Freitas C, Müller RH. Correlation between long-term stability of solid lipid nanoparticles (SLN) and crystallinity of the lipid phase. Eur J Pharm Biopharm 1999;47:125-32.
Liu T, Choi H, Zhou R, Chen IW. Quantitative evaluation of the reticuloendothelial system function with dynamic MRI. PLoS One 2014;9:e103576.
Cavalli R, Gasco MR, Chetoni P, Burgalassi S, Saettone MF. Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin. Int J Pharm 2002;238:241-5.
Wissing SA, Kayser O, Müller RH. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev 2004;56:1257-72.
Padhye SG, Nagarsenker MS. Simvastatin solid lipid nanoparticles for oral delivery: Formulation development and in vivo evaluation. Indian J Pharm Sci 2013;75:591-8.
Tupal A, Sabzichi M, Ramezani F, Kouhsoltani M, Hamishehkar H. Dermal delivery of doxorubicin-loaded solid lipid nanoparticles for the treatment of skin cancer. J Microencapsul 2016;33:372-80.
Attama AA, Umeyor CE. The use of solid lipid nanoparticles for sustained drug release. Ther Deliv 2015;6:669-84.
Thiresen G, Yahya EC, Pradeep K, Lisa CT, Girish M, Dinesh N, et al. A novel melt-dispersion technique for simplistic preparation of chlorpromazine-loaded polycaprolactone nanocapsules. Polymers 2015:7:1145-76.
Uprit S, Kumar Sahu R, Roy A, Pare A. Preparation and characterization of minoxidil loaded nanostructured lipid carrier gel for effective treatment of alopecia. Saudi Pharm J 2013;21:379-85.
Satheesh BN, Prabakaran L. formulation of ofloxacin loaded lipospheres with improved oral bioavailability. Pharm Nanotechnol 2013;1:306-15.
Sharma M, Sharma V, Panda AK, Majumdar DK. Development of enteric submicron particle formulation of papain for oral delivery. Int J Nanomedicine 2011;6:2097-111.
Subramanian AP, Jaganathan SK, Mandal M, Supriyanto E, Muhamad II. Gallic acid induced apoptotic events in HCT-15 colon cancer cells. World J Gastroenterol 2016;22:3952-61.
Elias DR, Poloukhtine A, Popik V, Tsourkas A. Effect of ligand density, receptor density, and nanoparticle size on cell targeting. Nanomedicine 2013;9:194-201.
Albanese A, Tang PS, Chan WC. The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annu Rev Biomed Eng 2012;14:1-6.
Karagoz B. Polymerization-induced self assembly (PISA)–control over the morphology of nanoparticles for drug delivery applications. Polym Chem 2014;5:350-5.
Nazanin H, Samantha G, Hongbin H, Gang B. The effect of nanoparticle size on in vivo pharmacokinetics and cellular interaction. Nanomedicine 2016;11:673-92.
Ekambaram P, Abdul HS. Formulation and evaluation of solid lipid nanoparticles of ramipril. J Young Pharm 2011;3:216-20.
Dudhipala N, Janga KY. Lipid nanoparticles of zaleplon for improved oral delivery by box-behnken design: Optimization, in vitro and in vivo evaluation. Drug Dev Ind Pharm 2017;43:1205-14.
Heidi AD. Efficacy of cancer drugs: Looking beyond the IC50. Chem Res Toxicol 2013; 26:1776-77.
Minakshi G, Jyoti D, Rakesh KM, Harish D. Therapies in cancer treatment: An overview. Int J Pharm Pharm Sci 2015;7:1-9.
Ksy H, Abhay R, Praveen S, Swati U, Hemanth K. Cancer nanotechnology: Nanoparticulate drug delivery for the treatment of cancer. Int J Pharm Pharm Sci 2015;7:40-6
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
